Cargando…
HSP90 Inhibitor, NVP-AUY922, Improves Myelination in Vitro and Supports the Maintenance of Myelinated Axons in Neuropathic Mice
[Image: see text] Hereditary demyelinating neuropathies linked to peripheral myelin protein 22 (PMP22) involve the disruption of normal protein trafficking and are therefore relevant targets for chaperone therapy. Using a small molecule HSP90 inhibitor, EC137, in cell culture models, we previously v...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2019
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588339/ https://www.ncbi.nlm.nih.gov/pubmed/31017387 http://dx.doi.org/10.1021/acschemneuro.9b00105 |
_version_ | 1783429225738403840 |
---|---|
author | Chittoor-Vinod, Vinita G. Bazick, Hannah Todd, Adrian G. Falk, Darin Morelli, Kathryn H. Burgess, Robert W. Foster, Thomas C. Notterpek, Lucia |
author_facet | Chittoor-Vinod, Vinita G. Bazick, Hannah Todd, Adrian G. Falk, Darin Morelli, Kathryn H. Burgess, Robert W. Foster, Thomas C. Notterpek, Lucia |
author_sort | Chittoor-Vinod, Vinita G. |
collection | PubMed |
description | [Image: see text] Hereditary demyelinating neuropathies linked to peripheral myelin protein 22 (PMP22) involve the disruption of normal protein trafficking and are therefore relevant targets for chaperone therapy. Using a small molecule HSP90 inhibitor, EC137, in cell culture models, we previously validated the chaperone pathway as a viable target for therapy development. Here, we tested five commercially available inhibitors of HSP90 and identified BIIB021 and AUY922 to support Schwann cell viability and enhance chaperone expression. AUY922 showed higher efficacy, compared to BIIB021, in enhancing myelin synthesis in dorsal root ganglion explant cultures from neuropathic mice. For in vivo testing, we randomly assigned 2–3 month old C22 and 6 week old Trembler J (TrJ) mice to receive two weekly injections of either vehicle or AUY922 (2 mg/kg). By the intraperitoneal (i.p.) route, the drug was well-tolerated by all mice over the 5 month long study, without influence on body weight or general grooming behavior. AUY922 improved the maintenance of myelinated nerves of both neuropathic models and attenuated the decline in rotarod performance and peak muscle force production in C22 mice. These studies highlight the significance of proteostasis in neuromuscular function and further validate the HSP90 pathway as a therapeutic target for hereditary neuropathies. |
format | Online Article Text |
id | pubmed-6588339 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Chemical
Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-65883392019-06-24 HSP90 Inhibitor, NVP-AUY922, Improves Myelination in Vitro and Supports the Maintenance of Myelinated Axons in Neuropathic Mice Chittoor-Vinod, Vinita G. Bazick, Hannah Todd, Adrian G. Falk, Darin Morelli, Kathryn H. Burgess, Robert W. Foster, Thomas C. Notterpek, Lucia ACS Chem Neurosci [Image: see text] Hereditary demyelinating neuropathies linked to peripheral myelin protein 22 (PMP22) involve the disruption of normal protein trafficking and are therefore relevant targets for chaperone therapy. Using a small molecule HSP90 inhibitor, EC137, in cell culture models, we previously validated the chaperone pathway as a viable target for therapy development. Here, we tested five commercially available inhibitors of HSP90 and identified BIIB021 and AUY922 to support Schwann cell viability and enhance chaperone expression. AUY922 showed higher efficacy, compared to BIIB021, in enhancing myelin synthesis in dorsal root ganglion explant cultures from neuropathic mice. For in vivo testing, we randomly assigned 2–3 month old C22 and 6 week old Trembler J (TrJ) mice to receive two weekly injections of either vehicle or AUY922 (2 mg/kg). By the intraperitoneal (i.p.) route, the drug was well-tolerated by all mice over the 5 month long study, without influence on body weight or general grooming behavior. AUY922 improved the maintenance of myelinated nerves of both neuropathic models and attenuated the decline in rotarod performance and peak muscle force production in C22 mice. These studies highlight the significance of proteostasis in neuromuscular function and further validate the HSP90 pathway as a therapeutic target for hereditary neuropathies. American Chemical Society 2019-04-24 /pmc/articles/PMC6588339/ /pubmed/31017387 http://dx.doi.org/10.1021/acschemneuro.9b00105 Text en Copyright © 2019 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes. |
spellingShingle | Chittoor-Vinod, Vinita G. Bazick, Hannah Todd, Adrian G. Falk, Darin Morelli, Kathryn H. Burgess, Robert W. Foster, Thomas C. Notterpek, Lucia HSP90 Inhibitor, NVP-AUY922, Improves Myelination in Vitro and Supports the Maintenance of Myelinated Axons in Neuropathic Mice |
title | HSP90 Inhibitor, NVP-AUY922, Improves Myelination
in Vitro and Supports the Maintenance of Myelinated Axons in Neuropathic
Mice |
title_full | HSP90 Inhibitor, NVP-AUY922, Improves Myelination
in Vitro and Supports the Maintenance of Myelinated Axons in Neuropathic
Mice |
title_fullStr | HSP90 Inhibitor, NVP-AUY922, Improves Myelination
in Vitro and Supports the Maintenance of Myelinated Axons in Neuropathic
Mice |
title_full_unstemmed | HSP90 Inhibitor, NVP-AUY922, Improves Myelination
in Vitro and Supports the Maintenance of Myelinated Axons in Neuropathic
Mice |
title_short | HSP90 Inhibitor, NVP-AUY922, Improves Myelination
in Vitro and Supports the Maintenance of Myelinated Axons in Neuropathic
Mice |
title_sort | hsp90 inhibitor, nvp-auy922, improves myelination
in vitro and supports the maintenance of myelinated axons in neuropathic
mice |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588339/ https://www.ncbi.nlm.nih.gov/pubmed/31017387 http://dx.doi.org/10.1021/acschemneuro.9b00105 |
work_keys_str_mv | AT chittoorvinodvinitag hsp90inhibitornvpauy922improvesmyelinationinvitroandsupportsthemaintenanceofmyelinatedaxonsinneuropathicmice AT bazickhannah hsp90inhibitornvpauy922improvesmyelinationinvitroandsupportsthemaintenanceofmyelinatedaxonsinneuropathicmice AT toddadriang hsp90inhibitornvpauy922improvesmyelinationinvitroandsupportsthemaintenanceofmyelinatedaxonsinneuropathicmice AT falkdarin hsp90inhibitornvpauy922improvesmyelinationinvitroandsupportsthemaintenanceofmyelinatedaxonsinneuropathicmice AT morellikathrynh hsp90inhibitornvpauy922improvesmyelinationinvitroandsupportsthemaintenanceofmyelinatedaxonsinneuropathicmice AT burgessrobertw hsp90inhibitornvpauy922improvesmyelinationinvitroandsupportsthemaintenanceofmyelinatedaxonsinneuropathicmice AT fosterthomasc hsp90inhibitornvpauy922improvesmyelinationinvitroandsupportsthemaintenanceofmyelinatedaxonsinneuropathicmice AT notterpeklucia hsp90inhibitornvpauy922improvesmyelinationinvitroandsupportsthemaintenanceofmyelinatedaxonsinneuropathicmice |